UGN-104
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Upper Urinary Tract Urothelial Carcinoma
Conditions
Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma
Trial Timeline
Aug 6, 2025 → Oct 1, 2027
NCT ID
NCT06774131About UGN-104
UGN-104 is a phase 3 stage product being developed by UroGen Pharma for Upper Urinary Tract Urothelial Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06774131. Target conditions include Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06774131 | Phase 3 | Recruiting |
Competing Products
20 competing products in Upper Urinary Tract Urothelial Carcinoma